Association of serum miR-99a level and metabolic dysfunction-associated steatotic liver disease, serum mTOR levels in patients with type 2 diabetes mellitus

作者：Yangyang Zhang, Yuqiong Zuo, Qian Chen, Yaqiang Cui, Yanxia Bao, Panpan Jiang, Jing Liu, Jing Liu, Jinxing Quan, Juxiang Liu, Juxiang Liu · 发表于：Frontiers in Endocrinology · 年份：2025 · DOI：10.3389/fendo.2025.1724108 · 被引用次数：1 · 研究领域：MicroRNA in disease regulation、Liver Disease Diagnosis and Treatment、Diabetes and associated disorders

Purpose This study was designed with the goal of exploring miR-99a expression in T2DM patients suffering from comorbid MASLD and clarifying the importance of miR-99a in this pathological context. Methods A total of 137 subjects were included in this study, including 50 T2DM patients with MASLD (T2DM +MASLD group),48 T2DM patients without MASLD (T2DM group), and 39 healthy subjects (Control group). We measured the levels of IL-6, mTOR and SOD in the serum of the subjects by ELISA. The plasma miR-99a levels was detected by RT-PCR. The correlation between serum miR-99a level and other indicators was analyzed. Results Serum miR-99a levels (median 0.79 vs 0.16 vs 0.03, P < 0.001) were significantly lower in the T2DM group than the healthy population and further decreased in the T2DM with MASLD patients ( P < 0.001). After adjusting for age, gender, illness duration and BMI, spearman correlation analysis showed that TG, HbA1c, FPG, HOMA-IR, Hs-CRP, IL-6, HDL-C, mTOR( P < 0.05) remained independently linked with serum miR-99a. And stepwise linear regression analysis showed that HbA1c, IL-6 and mTOR are independent serum miR-99a correlation variables ( P < 0.05). Moreover, the ROC results indicated that serum miR-99a has a high diagnostic value for T2DM with MASLD. In conclusion, serum miR-99a may be utilized as a screening biomarker for T2DM with MASLD. Conclusions These data highlight a potential role for miR-99a as a regulator of the comorbid incidence ...